Company news
Inhalation Sciences Sweden Ab (NGM:ISAB) news
Inhalation Sciences Sweden Ab news releases on 6ix. Latest, Aug 20, 2026: Inhalation Sciences to present the compelling results from the FDA-funded evaluation…
Press releases & updates
Inhalation Sciences to present the compelling results from the FDA-funded evaluation study of DissolvIt® at leading respiratory and inhalation drug development conferences
August 20, 2026
Inhalation Sciences receives IRS order worth approximately EUR 117,000
May 18, 2026
ISAB: Revenue and order intake surged, losses narrowed, and acquisition talks are advancing
May 11, 2026
Inhalation Sciences: Inhalation Sciences secures additional PreciseInhale® service orders worth SEK 350,000
March 24, 2026
Inhalation Sciences secures additional PreciseInhale® service orders worth SEK 350,000
March 24, 2026
ISAB: Sharp revenue drop and ongoing losses; financing and going concern remain key risks
February 27, 2026
Inhalation Sciences receives new IRS order for DissolvIt® worth approximately EUR 139,000
February 18, 2026
Inhalation Sciences: Inhalation Sciences receives new IRS orders worth EUR 52,000 from global pharmaceutical companies
January 27, 2026
Inhalation Sciences receives new IRS orders worth EUR 52,000 from global pharmaceutical companies
January 27, 2026
Inhalation Sciences receives major IRS order for DissolvIt® from leading global pharma company
December 22, 2025
Inhalation Sciences: Inhalation Sciences Presented FDA-Funded Study Results on DissolvIt® and the APRINHA Project at the DDL Conference
December 11, 2025
Inhalation Sciences receives purchase order worth 160 KEUR from international distributor for the US market
December 4, 2025
ISAB: Revenue fell, losses widened, but order intake and cash position improved after new financing
November 21, 2025
Inhalation Sciences: Inhalation Sciences hires advisors to evaluate potential acquirers of the company or the company's operations
November 4, 2025
Inhalation Sciences hires advisors to evaluate potential acquirers of the company or the company's operations
November 4, 2025
Inhalation Sciences: Inhalation Sciences receives IRS order from leading European university hospital
October 24, 2025
Inhalation Sciences receives IRS order from leading European university hospital
October 24, 2025
Inhalation Sciences: Inhalation Sciences to Present abstracts from the FDA-Funded Evaluation Study on DissolvIt® and the APRINHA Project at the 2025 DDL Conference
October 7, 2025
Inhalation Sciences to Present abstracts from the FDA-Funded Evaluation Study on DissolvIt® and the APRINHA Project at the 2025 DDL Conference
October 7, 2025
Inhalation Sciences: Inhalation Sciences receives service orders from recurring global pharma customers
October 2, 2025
Inhalation Sciences receives service orders from recurring global pharma customers
October 2, 2025
Inhalation Sciences: University of Liège highlights the value of PreciseInhale® in advancing Inhalation Research
September 19, 2025
Inhalation Sciences: Inhalation Sciences launches marketing campaign to increase awareness
September 17, 2025
Inhalation Sciences launches marketing campaign to increase awareness
September 17, 2025
ISAB: Revenue fell sharply, but cost cuts and new funding support a push toward profitability
August 29, 2025
Inhalation Sciences: Inhalation Sciences receives service order from recurring global pharmaceutical customer
July 1, 2025
ISAB: Record order backlog and FDA validation drive growth plans despite widening losses
May 16, 2025
ISAB: Revenue declined and losses increased, but FDA validation and new funding aim to drive growth
February 28, 2025
ISAB: Sales declined but cost control improved results; FDA collaboration and new partnerships drive outlook
November 20, 2024
ISAB: Operating result up 24% year-over-year, but sales and order intake declined
August 28, 2024